Acalabrutinib In Patients (Pts) With Waldenstrom Macroglobulinemia (Wm).
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2018）
摘要
2Bruton tyrosine kinase (BTK) is a clinically validated target in WM. Acalabrutinib is a highly selective, potent, covalent BTK inhibitor that we evaluated in a Phase 2 study of pts with treatment-naive (TN) or relapsed/refractory (R/R) WM.
更多查看译文
关键词
Waldenstrom macroglobulinemia,acalabrutinib,relapsed,refractory,treatment-naive,BTK inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要